-66.6%
RBLX vs MRNA
+511.3%
-577.9%
-74.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.3% | -2.2% | +6.6% | +4.4% |
| 7D | +12.4% | +5.5% | +6.9% | +12.1% |
| 30D | +19.7% | +158.7% | -139.1% | +9.5% |
| 3M | -0.1% | +182.1% | -182.2% | -9.0% |
| 6M | -35.7% | +151.8% | -187.6% | -41.1% |
| YTD | -46.6% | +393.6% | -440.1% | -51.6% |
| 1Y | -66.6% | +499.5% | -566.1% | -68.6% |
| All | -66.6% | +511.3% | -577.9% | -68.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling